Articles From: Genocea Named in Top Places to Work List by The Boston Globe to Gentherm Reports Results For Its 2014 Third Quarter And Nine Months


Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has been named as one of Boston’s Top Places to Work by The Boston Globe .
Sign-up for Genocea Named in Top Places to Work List by The Boston Globe investment picks
Genocea Biosciences, Inc. (NASDAQ: GNCA), a company developing T cell-directed vaccines and immunotherapies, today presented study results identifying a cluster of antigens that may be a biomarker of disease.
Sign-up for Genocea Profiles T cell Responses to Identify Antigens Associated with Malaria Episodes investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the third quarter ended September 30, 2014.
Sign-up for Genocea Reports Third Quarter 2014 Financial Results investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies, today announced that it has entered into a loan and security agreement with Hercules Technology Growth Capital, Inc. (NYSE:HTGC) for a term loan of up to $27.0 million.
Sign-up for Genocea Secures Debt Facility from Hercules Technology Growth Capital of up to $27 Million investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, announced today that it will hold a conference call and live audio webcast on November 6, 2014 at 9:00 a.m. ET to discuss financial results for the third quarter ended September 30, 2014.
Sign-up for Genocea to Announce Third Quarter 2014 Financial Results on November 6, 2014 investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the Stifel Nicolaus 2014 Healthcare Conference.
Sign-up for Genocea to Present at the Stifel Nicolaus 2014 Healthcare Conference investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present at the following upcoming conferences: Live webcasts of each presentation can be accessed by visiting the investor relations section of the Genocea website at http://ir.genocea.com .
Sign-up for Genocea to Present at Upcoming Investor Conferences investment picks
Presentations at SABCS and SUO Reveal Company's Ability to Detect Breast and Bladder Cancers in Blood and Urine, Respectively SAN ANTONIO , Dec.
Sign-up for Genomic Health Advances Development of Novel Liquid Biopsy-Based Cancer Tests investment picks
2014 San Antonio Breast Cancer Symposium Presentation Underscores the Value of Oncotype DX® as Chemotherapy Guide SAN ANTONIO , Dec.
Sign-up for Genomic Health Announces Presentation of First Prospective Outcomes Study of Oncotype DX® Breast Cancer Test investment picks
9% Increase in Test Volume; 5% Increase in Total Revenue CMS Announces Gapfill Pricing Methodology for Oncotype DX® Breast Cancer Test's Unique CPT Code Positive Ductal Carcinoma In Situ (DCIS) Clinical Validation Study Accepted for Oral Presentation at 2014 CTRC-AACR San Antonio Breast Cancer Symposium Two Clinical Studies Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast and Bladder Cancers to be Presented at Upcoming Medical Meetings Conference Call Today at 4:30 p.m. ET REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Third Quarter 2014 Financial Results and Reports Continued Growth in U.S. Invasive Breast Cancer Business investment picks
REDWOOD CITY, Calif.
Sign-up for Genomic Health to Present at the 26th Annual Piper Jaffray Healthcare Conference investment picks
REDWOOD CITY, Calif.
Sign-up for Genomic Health to Present at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
REDWOOD CITY, Calif.
Sign-up for Genomic Health to Present at the Credit Suisse Annual Healthcare Conference investment picks
Innovative collaboration helps financial institutions streamline their margin and collateral management processes NEW YORK , Nov.
Sign-up for Genpact and Lombard Risk Launch New Collateral Management Solution for Capital Markets investment picks
2014/11/4
Unique focus on enterprise operations' art of the possible through collective insights of a specialized ecosystem NEW YORK , Nov.
Sign-up for Genpact Formalizes Research Institute for Intelligent Operations investment picks
2014/11/5
Revenues of $588.1 Million, Up 9.9% Adjusted Income from Operations of $88.5 Million Cash Flow from Operations of $85.7 Million NEW YORK , Nov.
Sign-up for Genpact Reports Results for the Third Quarter of 2014 investment picks
2015/1/13
Results indicate customer satisfaction is single most common challenge for P&C insurers NEW YORK , Jan.
Sign-up for Genpact Survey Results: Insurers Address Enterprise Challenges Using Advanced Operating Models investment picks
2015/1/15
238 senior banking executives polled in independent research commissioned by Genpact reveals untapped potential NEW YORK , Jan.
Sign-up for Genpact Survey Results: Retail and Commercial Bank COOs Say Firms Can Unleash Over $500 Million A Year Through Advanced Operations investment picks
2014/11/18
Independent research shows strong focus on cost and challenges with analytics and data as well as the value of shared operating structures NEW YORK , Nov.
Sign-up for Genpact Survey: Chief Procurement Officers' Strategic Perspectives and Operating Model Struggles Differ From Their Peers investment picks
2015/1/14
NEW YORK , Jan.
Sign-up for Genpact to Host Investor and Analyst Day in New York City on February 27, 2015 investment picks
http://media.marketwire.com/attachments/201401/70451_gen.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1163356&ProfileId=051205&sourceType=1 ZEELAND, MI --
Sign-up for Gentex Corporation Declares 100% Stock Dividend and Announces Share Repurchases of $20 Million investment picks
http://media.marketwire.com/attachments/201401/70451_gen.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162535&ProfileId=051205&sourceType=1 ZEELAND, MI --
Sign-up for Gentex Declares Quarterly Cash Dividend investment picks
2014/12/17
http://media.marketwire.com/attachments/201401/70451_gen.jpg http://media.marketwire.com/attachments/201412/TN-297151_Gentex_Full_Display_Mirror.jpeg.jpg The rearview mirror's view is often obstructed by headrests, passengers and roof support pillars.
Sign-up for Gentex Expands New Product Offerings investment picks
http://media.marketwire.com/attachments/201401/70451_gen.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1167084&ProfileId=051205&sourceType=1 ZEELAND, MI --
Sign-up for Gentex Reports Fourth Quarter 2014 Earnings Release Date and Conference Call investment picks
2014/10/23
NORTHVILLE, Mich.
Sign-up for Gentherm Announces Date For 2014 Third Quarter And Nine-Month Results News Release And Conference Call investment picks
2014/12/23
Site near Hanoi to Serve Fast Growing Asian Market NORTHVILLE, Mich.
Sign-up for Gentherm Begins Construction Of New Manufacturing Facility In Vietnam investment picks
Josh Micklos Named General Manager, National Accounts, for Bedding Division; Stephen Palmer Named Director, U.S. Sales, of GPT NORTHVILLE, Mich.
Sign-up for Gentherm Opens Houston Office For Bedding Division, Global Power Technologies Group (GPT) investment picks
2014/10/30
Net Income in Both Periods More than Doubles NORTHVILLE, Mich.
Sign-up for Gentherm Reports Results For Its 2014 Third Quarter And Nine Months investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Genocea Named in Top Places to Work List by The Boston Globe to Gentherm Reports Results For Its 2014 Third Quarter And Nine Months
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent